

FOI 2977

31st March 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Response:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	16
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	Not centrally held
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	35
1.7 Ribociclib (Kisqali)	18
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	1
1.10 Olaparib (Lynparza)	1

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Response:

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	Not centrally held
2.2 Ribociclib (Kisqali)	0

2.3 Olaparib (Lynparza)

Not centrally held

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Response:

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	Not centrally held
3.2 Ribociclib (Kisqali)	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Response:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	Not centrally held
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	Not centrally held
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	Not centrally held

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024?

Response:

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	1
5.2 Locally advanced or metastatic breast cancer	Not centrally held

OVARIAN CANCER and ENDOMETRIAL CANCER



Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
6.1 Niraparib (Zejula)	0
6.2 Rucaparib (Rubraca)	0
6.3 Olaparib (Lynparza)	0

Q7. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
7.1 Olaparib in total	0
7.2 Olaparib monotherapy	0
7.3 Olaparib + bevacizumab in combination	0
7.4 Bevacizumab total	0
7.5 Bevacizumab monotherapy	0
7.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	0

Q8. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	0
8.2 Pembrolizumab (Keytruda)	0

8.3 Lenvatinib (Lenvima)

0

Q9. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
9.1 Dostarlimab monotherapy	0
9.2 Dostarlimab in combination with Chemotherapy	0
9.3 Pembrolizumab monotherapy	0
9.4 Pembrolizumab + Lenvatinib in combination	0
9.5 Lenvatinib monotherapy	0

** This information is not recorded centrally. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of departments it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.**

Email: Foi.Team@Southerntrust.hscni.net